Robert Weisman

Weisman covers the healthcare and life sciences industries for the Business section. He was a business reporter and editor for the Hartford Courant and the Seattle Times before joining the Globe in 2000.

Latest stories

FDA rejects Vertex’s application for expanded use of drug

By , Globe Staff

The FDA rebuffed the company’s application to sell its first cystic fibrosis drug to a new subset of patients.

Mass. Life Sciences Center adviser resigns

By , Globe Staff

Harvey Lodish questioned the Baker administration’s commitment to the center and to independent review of proposals seeking state funding.

Editas’s surge brightens IPO outlook

By , Globe Staff

Editas Medicine, a Cambridge startup, rose 12.5 percent. China’s BeiGene Ltd. climbed more than 18 percent.

Mersana Therapeutics expands partnership with Takeda

By , Globe Staff

Takeda will get the rights to market the Cambridge company’s lead cancer-fighting drug candidate outside the US and Canada.